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Summary 
Background: Head and neck squamous cell carcinoma,
including oral cancer, is the sixth most common cancer
worldwide. Despite advances in surgery and treatment, the
5-year survival rate has not improved significantly. There -
fore, reliable molecular markers for oral cancer progression
are badly needed.
Methods: We conducted a copy number analysis to esti-
mate amplification status of c-myc, cycD1 and EGFR onco-
genes, mutational PCR-SSCP analysis to determine activa-
tion of H-ras oncogene and inactivation of TP53 tumour
suppressor gene and methylation specific PCR analysis to
evaluate hypermethylation of p16 and MGMT genes. 
Results: c-myc oncogene was amplified in 56.7%, cycD1 in
20% and EGFR in 16.7% of Oral Squamous Cell Carci -
noma (OSCC) cases while H-ras was activated in 33.3% of
samples. Amplification of c-myc was significantly associat-
ed with the tumour grade 2. Interestingly, EGFR and H-ras
alterations were mutually exclusive. p16 and MGMT were
inactivated by hypermethylation in 30% and 13.3% of
Kratak sadr`aj
Uvod: Skvamocelularni karcinomi glave i vrata (HNSCC)
uklju~uju}i i skvamocelularni karcinom usne duplje (OSCC)
ubrajaju se u {est naj~es}ih tipova humanih maligniteta.
Uprkos zna~ajnim napredcima u hirur{kom i terapijskom
tretmanu, stopa petogodi{njeg pre`ivljavanja kod ovog tipa
maligniteta nije zna~ajnije popravljena. Upravo zato, defin-
isanje pouzdanih molekularnih markera progresije kod
OSSC predstavlja apsolutni prioritetet.
Metode: Amplifikacioni status c-myc, cycD1 i EGFR gena
odre|en je pomo}u eseja za detekciju broja genskih kopi-
ja, aktivacija H-ras onkogena i inaktivacija TP53 tumor
supresora odre|ena je PCR-SSCP mutacionom analizom, a
hipermetilacija promotora p16 i MGMT gena je ispitana
metil specifi~nim PCR-om (MSP).
Rezultati: Amplifikacija c-myc onkogena detektovana je
kod 56,7%, cycD1 onkogena kod 20%, a EGFR onkogena
kod 16,7% analiziranih oralnih skvamocelularnih carcino-
ma. Istovremeno, mutaciona aktivacija H-ras onkogena
detektovana je kod 33,3% ispitanih uzoraka. Amplifikovani
List of Abbrevations: HNSCC, Head and Neck Squamous
Cell Carcinoma; OSCC, Oral Squamous Cell Carcinoma;
EGFR, epidermal growth factor receptor; MGMT, O6-
methylguanine DNA methyltransferase; cycD1, cyclin D1;
PCR, Polymerase Chain Reaction; SSCP, Single Strand
Conformation Polymorphism.
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Introduction
Head and neck squamous cell carcinoma
(HNSCC), including oral cancer, is the sixth most
common cancer, with an annual incidence of more
than 500,000 cases worldwide (1). Oral squamous
cell carcinoma (OSCC), which arises from the oral
mucosa lining, is the most frequent malignant neo-
plasm of the head and neck region and accounts for
over 90% of these tumours (2). This aggressive malig-
nancy is associated with high mortality and with
severe physical, emotional, and psychosocial damage
among the rare long-term survivors. Despite
advances in surgery and treatment, the 5-year sur-
vival rate for patients diagnosed with oral squamous
cell carcinomas has not improved significantly and
remains at about 50% (3, 4). The prognosis of OSCC
is influenced by many factors, such as performance
status, TNM staging and pathological grading of dif-
ferentiation. However, these factors are not sufficient
in predicting the outcome. This motivates the search
for factors with prognostic relevance in order to better
tailor the individual management of OSCC patients.
Recent research has focused on identification of
molecular prognostic markers that could stage
patients in more meaningful prognostic groups. 
Oral carcinogenesis is a highly complex multi-
factorial multi-step process that is driven by the accu-
mulation of multiple genetic and epigenetic alter-
ations. Majority of them represent the activation of
oncogenes and the inactivation of tumour suppressor
genes, meaning that numerous oncogenes and
tumour suppressor genes are implicated in oral car-
cinogenesis. The most thoroughly studied oncogenes
implicated in the pathogenesis and prognosis of
OSCC are epidermal growth factor receptor (EGFR),
and members of gene families – ras, myc and cyclins.
EGFR, the biological receptor of EGF and TGF-a, is
frequently overexpressed in oral cancer and was
shown to result from EGFR gene amplification in 30%
of oral cancers (5). Similarly, c-myc oncogene, a tran-
scription factor that regulates important processes
such as stimulation of proliferation and inhibition of
differentiation is found to be amplified in 20 to 40%
of oral cancers (6, 7). Some studies showed that
members of the ras oncogene family are overex-
pressed in oral cancer, too. However, H-ras is usually
activated by point mutations in codons 12, 13 and
61. The frequency of H-ras mutations in OSCC varies
and ranges from 5% in Western countries (8) up to
35% in Asian population (9). Finally, cyclins are
essential in controlling the cell cycle. Among cyclins,
cyclin D1 appears to be the most strongly implicated
in human oncogenesis since its overexpression plays
an essential role in the transition between G1 and S
phase in proliferating cells (10). Amplification of
cyclin D1 gene was reported in 25–70% of oral can-
cers (11). 
Among tumour suppressors the most widely
studied genes in OSCC pathogenesis are TP53 and
p16. Protein products of these genes control the cell
cycle and are involved in the inhibition of cell prolifer-
ation. Structural and/or functional alterations in these
genes produce uncontrolled cell proliferation.
Therefore, it is not surprising that reported frequen-
cies of TP53 alteration ranges from 20–90% in
HNSCC, depending on the methodologies, type of
tumour material and heterogeneity of tumour site
examined (12). 
However, the available evidence about the mo -
le cular markers still remains inconclusive. Accor -
dingly, there is a continuous need to define the most
important biological markers for OSCC progression
and invasiveness. 
cases. Co-alteration of cycD1 and p16 were not observed
in any of the analyzed samples. TP53 was inactivated in
56.7% of samples and was significantly associated with
progression of OSCC, grade 2 and stage 2. Moreover,
TP53 and c-myc oncogene were simultaneously altered in
grade 2 OSCC. 
Conclusions: The most promising marker of OSCC pro-
gression remains the TP53 tumour suppressor, which is the
most frequently mutated gene in oral cancers. Since there
is synergism between TP53 and c-myc, it seems that co-
alteration of these two genes could be also a good marker
of OSCC progression from grade1 to grade 2 tumours.
Keywords: c-myc, oncogenes, oral squamous cell carci-
noma, TP53, tumour progression, tumour suppressors
c-myc, statisticki zna~ajno korelira sa gradusom 2 OSCC.
Posebno intrigantan je bio nalaz po kom se onkogene akti-
vacije u EGFR i H-ras genu medjusobno isklju~uju.
Hipermetilacija promotora p16 gena detektovana je kod
30%, a MGMT kod 13,3% analiziranih uzoraka. Ko-altera-
cije cycD1 i p16 gena nisu zapa`ene ni u jednom od ana-
liziranih uzoraka. Inaktivacija TP53 gena detektovana je
kod 56,7% uzoraka i utvr|eno je da statisti~ki zna~ajno
korelira sa gradusom 2 i statusom 2 OSCC. Pored ovoga,
utvr|eno je da statisti~ki zna~ajan broj uzoraka gradusa 2,
sa aktiviranim TP53 genom ima istovremeno aktiviran i
c-myc onkogen. 
Zaklju~ak: TP53, naj~e{}e mutirani gen u oralnim karcino-
mima, ostaje za sada i najpouzdaniji marker progresije kod
OSCC. Obzirom na detektovani sinergizam izme|u TP53 i
c-myc gena, mo`emo re}i da su istovremene promene u
ova dva gena jo{ pouzdaniji pokazatelj progresije OSSC iz
gradusa 1 u gradus 2.
Klju~ne re~i: c-myc, onkogeni, progresija tumora,
TP53, tumor supresori, skvamocelularni karcinom usne
duplje
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The aim of this study is to provide additional
information regarding molecular markers with the
greatest potential for predicting clinical outcome in
patients with OSCC. These include regulators of the
cell cycle: p16, TP53 and cyclin D1, DNA repair gene
MGMT and genes of the commonly activated signal-
ing pathway in tumorigenesis, the EGFR/H-ras/c-myc
pathway. In addition, we also describe a modification
of a method for copy number analyses which was
used to investigate amplification of c-myc and cycD1
oncogenes.
Materials and Methods
Tissue samples and DNA Extraction
Genomic DNA used in this study was isolated
from 30 fresh frozen, surgically resected SCC of oral
cavity collected at the Clinic of Maxillofacial Surgery,
School of Dentistry, University of Belgrade. For each
obtained tumour sample written consent and
approval were acquired according to the ethical stan-
dards laid down in the1964 Declaration of Helsinki,
the International Ethical Guidelines for Biomedical
Research Involving Human Subjects (CIOMS),
Geneva 1993, and the Guidelines for Good Clinical
Practice CPMP/ICH/135/95), September 1997.
Genomic DNA was extracted from thirty frozen
tumour tissue samples and five blood control samples
according to the standard phenol/chloroform extrac-
tion procedure described by Sambrook and col-
leagues (13). The quality of the extracted DNA was
verified by agarose gel electrophoresis and the con-
centrations were assessed spectrophotometrically.
Isolated DNA was stored at +4 °C until further analy-
ses.
Copy number analysis by quantitative real time
PCR
In order to estimate amplification status of the
two most often amplified oncogenes in human
tumours including OSCC, c-myc and cycD1, a
TaqMan based assay was created. We used RNase-P
gene as the internal control (reference gene). The
rationale for this was that RNase-P gene is a single
copy gene and is therefore most suitable for normal-
ization in copy number quantification analysis. 
Our assay included forward and reverse primers
for c-myc and cycD1 oncogenes as well as highly spe-
cific 6-Fam-TAMRA labeled probes for them. For the
analysis of cycD1, the following probe and primers
were used: fluorescent TaqMan Probe 6-FAM-5’-
CAGCCT TGT TGT T TACGGCCTCT T TGAG-3’-
TAMRA; primer cycD1_F 5’-GGACAACGGGCG-
GATAGAG-3’; and primer cycD1_R 5’-CACA GTCA
 TCCCAG GGTTTAACA-3’. For the analysis of c-myc,
the following probe and primers were used: TaqMan
Probe 6-FAM-5’-AGAAGCCGCTCCACATACAGTC-
CTGG-3’-TAMRA; primers c-myc_F 5’-GGACGAC-
GAGACCTTCATCAA-3’; and c-myc_R 5’-CCAGCTT -
CTCTGAGACGAGCTT-3’. In addition, TaqMan®
Copy Number Reference Assay, RNase P, was used
for internal control (accession # 4316831, Applied
Biosystems). 
The experiments were set in 96-well plastic
plates, with samples prepared in duplicates, in total
reaction volume of 20 mL, with primers /probe ratio
3:1 (0.1 mmol/L probe : 0.3 mmol/L primers), 1x
TaqMan Master Mix and 150 ng of tested DNA per
reaction. Each plate contained at least two controls,
DNAs isolated from the blood of healthy individuals.
This control samples were used as calibrators. PCR
reactions were carried out in the ABI Prism 7500
Sequence Detection System at 50 °C for 2 minutes,
95 °C for 10 minutes, followed by 40 cycles at 95 °C
for 15 seconds, and 60 °C for 1 minute. The experi-
mental threshold was calculated based on the mean
baseline fluorescence signal from cycle 3 to 15 plus
10 standard deviations. The point at which the ampli-
fication plot crosses this threshold is defined as Ct,
which represents the cycle number at this point and is
inversely proportional to the number of target copies
present in the initial sample. A mean value of each Ct
duplicate was used for further calculation. Each run
included a no-template control, as well. The obtained
results were analyzed by RQ Study Add ON software
for 7500 v 1.3 SDS instrument with a confidence
level of 95% (p<0.05).
Differential PCR
Amplification status of EGFR oncogene was
determined by duplex PCR reaction that engaged two
pairs of primers, one for the target gene (EGFR) and
the other for the reference gene (b-actin). For differ-
ential PCR analysis, a 110-bp fragment of the EGFR
gene was co-amplified with a 168-bp fragment of b-
actin (ACTB) gene. The primer sequences were as fol-
lows: EGFR_F 5’-AGCCATGCCCGCATTAGC TC-3’
and EGFR_R 5’-AACCCTTCAACGTAAGG AAA-3’ for
EGFR, and ACTB_F 5’-CTCTTTTCTTTCCCGATAG-
GT-3’ and ACTB_R 5’-CTCCAGCTTCTCGTAGGGTC
-3’ for the ACTB. D-PCR was performed in the total
reaction volume of 25 mL with 150 ng of DNA, 1×
PCR buffer (50 mmol/L KCl, 10 mmol/L Tris–HCl, pH
8.3, 0.01% gelatin), 1.5 mmol/L MgCl, 0.2 mmol/L
each dNTP, 1 mmol/L each of four primers, 1U Taq -
Polymerase. Thermal cycling included thirty repeats
of denaturation at 95 °C/1 minute, annealing at 58
°C/1 minute and extension at 72 °C/1 minute, with
initial denaturation (95 °C/10 minutes) before and
final extension (72 °C/10 minutes) after the repeating
temperature steps. Generated PCR products were
applied to 9% polyacrylamide gel for electrophoresis,
stained with silver-nitrate, photographed and analyzed
by Image Quant 5.2 by comparing the median pixel
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intensity in a given/selected area of two bands (EGFR
and ACTB) in the same lane (sample). When median
pixel intensity of EGFR band was equal or higher then
25% of median pixel intensity of ACTB, it was inter-
preted as gene amplification.
PCR-SSCP analysis of TP53 and H-ras genes
The most frequently mutated exons of TP53
tumour-suppressor gene (5–9) and sequences sur-
rounding the hot-spot codons of H-ras oncogene
(12,13 and 61) were amplified by PCR and subjected
to further mutational screening by single strand con-
formation polymorphism (SSCP). Primers and PCR
conditions are given in Table I, and conditions for
SSCP mutational screening have been described ear-
lier (14). In brief, amplicons were mixed with double
volume of formamide containing 0.05% xylene cianol
and 0.05% brom phenol blue, denatured at 95 °C for
5 minutes, cooled on ice for 1 minute and loaded on
non-denaturating polyacrilamide gels (PAA). Con cen -
tration of PAA gels ranged from 7–12% depending on
the amplicon length, and they were prepared with or
without glycerol (10% in final) depending on the tem-
perature at which electrophoresis was run. In order to
avoid false positives or negatives, samples were exam-
ined under at least two different SSCP conditions,
including different crosslink (%C=5.26; %C=3.6),
temperature, ion charge, etc. Genomic DNA isolated
from the blood of five healthy individuals was used as
negative control.
Bisulfite modification of DNA and 
methylation-specific PCR
The methylation status of promoter region of
p16 and MGMT genes was determined by methyla-
tion-specific PCR (MSP). Extracted genomic DNA was
modified by bisulfite treatment according to proce-
dure described by Herman et al (15). In brief, 500ng
of total genomic DNA was denatured with 3 mol/L
NaOH and bisulfate modification done overnight (eg.
eighteen hours) at 55 °C. Besides tumour specimens,
totally methylated and unmethylated human DNAs
were always included in the bisulfite treatment proce-
dure as controls. To estimate methylation status of the
promoter regions of p16 and MGMT genes, a set of
four primers per each gene was used: one pair for the
detection of methylated CpG-cytosine and the other
for the identification of unmethylated CpG-cytosine.
Primers for p16 were as follows: p16_MF 5’-TTAT -
TAGAGGGTGGGGCGGATCGC-3’ and p16_MR 5’-
GACCCCGAACCGCGACCGTAA-3’ for methylated
CpG- cytosine producing an amplicon 150 bp long,
Table I Primers and PCR conditions for the amplification of H-ras and TP53 genes.
Primer Gene Length (bp) Primer sequence Temperature profile
H1S exon 1
63
5’-GACGGAATATAAGCTGGTGG-3’ 94 °C (85s) 60 °C (95s) 72 °C (72s)
H1A H-ras gene 5’-TGGATGGTCAGCGCACTCTT-3’ 40 cycles
H12,13-5’ exon 1
123
5’-ATGACGGAATATAAGCTGGT-3’ 95 °C(60s) 56 °C(60s) 65 °C(60s)
H12,13-3’ H-ras gene 5’-ATATCTCCACTCGGACCGC-3’ 35 cycles
H2S exon 2
73
5’-AGACGTGCCTGTTGGACATC-3’ 94 °C(95s) 60 °C(110s) 72 °C(80s)
H2A H-ras gene 5’-CGCATGTACTGGTCCCGCAT-3’ 40 cycles
H61-5’ exon 2
109
5’-AGGTGGTCATTGATGGGGAG-3’ 95 °C(60s) 56 °C(60s) 65 °C(60s)
H61-3’ H-ras gene 5’-AGGAAGCCCTCCCCGGTGCG-3’ 35 cycles
E5S exon 5
269
5’-TGTTCACTTGTGCCCTGACT-3’ 95 °C(60s) 60 °C (60s)
E5A p53 gene 5’-CAGCCCTGTCGTCTCTCCAG-3’ 35 cycles
Ep5-1 exon 5
238
5’-CCTTCCTCTTCCTACAGTAC-3’ 94 °C(15s) 55 °C(15s) 72 °C(90 °C)
Ep5-2 p53 gene 5’-CCCAGCTGCTCACCATCGCT-3’ 35 cycles
E6S exon 6
181
5’-GCCTCTGATTCCTCACTGAT-3’ 95 °C(60s) 60 °C(60s) 72 °C(30s)
E6A p53 gene 5’-TTAACCCCTCCTCCCAGAGA-3’ 35 cycles
E7S exon 7
171
5’-ACTGGCCTCATCTTGGGCCT-3’ 95 °C(60s) 60 °C (60s)
E7A p53 gene 5’-TGTGCAGGGTGGCAAGTGGC-3’ 35 cycles
Ep7-1 exon 7
138
5’-GTGTTATCTCCTAGGTTGGC-3’ 94 °C(15s) 55 °C(15s) 72 °C(90 °C)
Ep7-2 p53 gene 5’-AAGTGGCTCCTGACCTGGAG-3’ 35 cycles
E8S exon 8
229
5’-TAAATGGGACAGGTAGGACC-3’ 95 °C(60s) 60 °C (60s)
E8A p53 gene 5’-TCCACCGCTTCTTGTCCTGC-3’ 35 cycles
Ep8-1 exon 8
234
5’-CCTTACTGCCTCTTGCTTC-3’ 94 °C(15s) 55 °C(15s) 72 °C(90 °C)
Ep8-2 p53 gene 5’-TGAATCTGAGGCATAACTGC-3’ 35 cycles
E9S exon 9
210
5’-ACTAAGCGAGGTAAGCAAGC-3’ 95 °C(60s) 60 °C (60s)
E9A p53 gene 5’-CTGGAAACTTTCCACTTGAT-3’ 35 cycles
and p16_UF 5’-TTATTAGAGGGTGGGGTGGATTGT
-3’ and p16_UR 5’-CAACCCCAAACCACAACCATAA
-3’ for unmethylated CpG- cytosine producing an
amplicon 151bp long. Primers for MGMT were:
MGMT_MF 5’-TTTCGACGTTCGTAGGTTTTCGC-3’
and MGMT_MR 5’-GCACTC TTCCGAA AA CGA AA -
CG-3’ producing amplicons of 81bp, and MGMT_UF
5’-TTTGTGTTTGATGTTTGTAGGTTTTTGT-3’ and
MGMT_UR 5’-AACTCCACACTCTTCCAAAAACAA -
AAA-3’ producing amplicons of 93 bp. Methylation
specific PCR either for p16 or for MGMT gene, was
set up in total reaction volume of 50 mL with the fol-
lowing final concentrations of reaction components:
1×PCR buffer, 6.7 mmol/L MgCl2, 1.25 mmol/L
dNTPs, 0.6–0.8 mmol/L each of primers, 0.4 mg/mL
BSA, 5% DMSO and 50–100 ng of modified DNA.
All reactions were hot started at 95 °C for 5 minutes
before the 1.5 U of TaqDream Polymerase (Fer men -
tas Life Sciences, Lithuania) was added. Reactions
were carried out in GeneAmpR PCR System 9700
(Applied Biosystems, Foster City, CA,USA) for 40
cycles with the temperature profiles that included: 45
seconds of denaturation at 95 °C, 45 seconds of
annealing at the temperature that depended on used
upper listed primers (65 °C/p16M; 60 °C/p16U; 57
°C/MGMT_M and U), and 1 minute of extension at
72 °C. Each MSP reaction was ended with the final
extension at 72 °C for 5 minutes.
Statistical analysis
Significant differences between the data sets
were determined by STATISTICA 6.0 software
(StatSoft, Inc., Tulsa, USA). The correlations between
clinicopathological parameters and alterations of
TP53, MGMT, p16, c-myc, cycD1 and EGFR genes
were evaluated using Fisher exact test. Statistical dif-
ferences were considered significant when P was <
0.05 (*) and P<0.01 (**).
Results
Amplification of c-myc, cycD1 and EGFR 
oncogenes
We determined amplification status of c-myc
and cycD1 oncogenes by Quantitative Real Time PCR
using modification of a method described by Akervall
and colleagues (16). Namely, we used RNase P as a
reference gene for the normalization and performed
quantification by 2-DDCt method (17). DNA from
healthy individuals was used as a calibrator. We inter-
preted results of quantification > 2 as an abnormali-
ty, signifying oncogene amplification. Obtained
results are summarized in Table II. Specifically, c-myc
oncogene was amplified in 17 patients out of 30
(56.7%) while cycD1 was amplified in 6 patients or
20% of cases. 
Unlike c-myc and cycD1, amplification of EGFR
oncogene was assessed by differential PCR (Figure 1)
and was found to be amplified in only 5 patients
(16.7%).
Further, we analyzed relationship between
altered oncogenes and histopathological characteris-
tics (Table II) of patients. Amplification of c-myc
showed to be significantly associated with the grade 2
of the disease (Table III). Alterations of cycD1 and
EGFR have not revealed any association. 
Mutational status of H-ras oncogene and TP53
tumour suppressor gene
H-ras oncogene is usually activated by point
mutations in codons 12, 13 and 61. Therefore, we
analyzed mutational status of H-ras oncogene by
PCR-SSCP and obtained that it was activated in
33.3% of patients (Table II). Analysis of relationship
with histopathological characteristics did not reveal
any significant association.
On the other hand, mutational analysis of TP53
revealed that it was inactivated in 17 out of 30
(56.7%) patients (Table III). Moreover, inactivation of
TP53 was significantly associated with progression of
tumour, grade 2 (Table IV) and stage 2 (Table V). 
Methylation status of p16 and MGMT tumour
suppressor genes
Methylation status of p16 and MGMT was
assessed by MSP-PCR (Figure 2). Obtained results
revealed that p16 was hypermethylated in 9 patients
(30%) and MGMT only in 4 out of 30 (13.3%). No
correlation was found with histopathological charac-
teristics of the patients.
Relationship between alterations of analyzed
genes
In order to reveal possible association among
studied genes, we further analyzed whether there
were co-alterations between any of them during the
evolution of tumour. The only significant association
we found was the one between c-myc oncogene and
TP53 tumour suppressor gene in patients with grade
2 OSCC. Namely, Fisher exact test revealed that fre-
quency of TP53 mutations was significantly higher in
grade 2 tumours with amplified c-myc (Table VI). In
other words, c-myc oncogene and TP53 tumour sup-
pressor gene were simultaneously altered in grade 2
tumours of oral cavity. All remaining combinations
revealed no co-alterations of any significance.
However, it is interesting to notice that EGFR was
never amplified in samples that have had mutated H-
ras. Similarly, amplification of cycD1 and inactivation
of p16 have not been detected in the same patient.
In other words, alterations in genes from these two
sets are mutually exclusive.
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Figure 1 Differential PCR for determination of EGFR ampli-
fication status. Arrow indicates a sample with amplified EGFR
gene.
aN – number of patients per group; *indicates statistically sig-
nificant values, p≤0.05.
aN – number of patients per group; *indicates statistically sig-
nificant values, p≤0.01.
Table III Association between c-myc amplification and
tumour grade.
Variables
Amplification of c-myc oncogene
YES
Na (%)
NO
N (%) p value
G1 5 (16.7) 9 (30.0)
G2 12 (40.0) 4 (13.3) p = 0.0355*
Table IV Association between mutational status of p53 and
tumour grade.
Variables
Mutated TP53
YES
Na (%)
NO
N (%) p value
G1 3 (10.0) 11 (36.7)
G2 14 (46.7) 2 (6.6) p = 0.0004*
aN – number of patients per group; *indicates statistically sig-
nificant values, p≤0.05.
Table V Association between mutational status of p53 and
tumour stage.
Variables
Mutated TP53
YES
Na (%)
NO
N (%) p value
T1 4 (14.3) 9 (32.1)
T2 11 (39.3) 4 (14.3) p = 0.0298*
Table II Molecular and histopathological characteristics of patients.
Patients c-myc amp Hras mut cycD1 amp EGFR amp TP53 mut p16 met MGMT met Grade pT stage
M1 1 1 0 0 1 1 0 G2 T3
M2 0 1 0 0 0 0 0 G1 T1
M3 1 1 1 0 1 0 0 G2 T2
M4 0 1 1 0 0 0 0 G1 T1
M5 1 0 0 0 1 1 1 G1 T2
M6 1 0 0 0 0 1 0 G1 T2
M7 1 0 0 0 0 1 0 G1 T2
M8 1 1 0 0 1 0 0 G2 T2
M9 0 0 0 0 1 0 0 G2 T2
M10 1 1 0 0 0 0 0 G1 T2
M11 1 0 0 0 1 1 0 G2 T2
M12 1 0 0 0 0 0 1 G1 T1
M13 0 0 0 0 1 1 0 G2 T2
M14 0 1 0 0 0 1 0 G1 T1
M15 1 1 0 0 1 0 1 G2 T3
M16 1 0 0 1 1 0 0 G2 T2
M17 0 0 1 0 1 0 0 G1 T2
M18 1 0 0 1 1 1 0 G2 T1
M19 1 0 1 1 1 0 0 G2 T2
M20 0 0 0 1 1 0 0 G1 T1
M21 0 0 0 0 0 1 0 G2 T2
M25 1 1 0 0 0 0 0 G2 T1
M26 1 0 0 0 1 0 0 G2 T1
M27 0 0 0 0 1 0 0 G2 T2
M28 1 1 0 0 1 0 1 G2 T4
M29 1 0 1 0 1 0 0 G2 T1
M30 0 0 0 1 0 0 0 G1 T1
M31 0 0 0 0 0 0 0 G1 T1
M32 0 0 0 0 0 0 0 G1 T1
M33 0 0 1 0 0 0 0 G1 T1
1 – gene alteration is present; 0 – gene is wt.
Discussion
In the present study we investigated the prog-
nostic value of frequently altered oncogenes and
tumour suppressor genes in 30 cases of Oral Squa -
mous Cell Carcinoma. To that end, we conducted a
copy number analysis to estimate amplification status
of c-myc, cycD1 and EGFR oncogenes, mutational
analysis to determine activation of H-ras oncogene
and inactivation of TP53 tumour suppressor gene and
methylation analysis to evaluate methylation status of
p16 tumour suppressor and MGMT DNA repair gene.
Obtained alterations were correlated with each other
and with histopathological parameters.
Copy number analysis revealed unusually high
frequency of c-myc amplification (56.7%) in this
cohort, which was considerably above previously
reported 20 – 40% (6–8). Tumorigenicity of the c-myc
protein is ascribed to the promotion of cell prolifera-
tion and inhibition of apoptosis (18, 19). Its overex-
pression in OSCC is the result of gene amplification
and is usually associated with poorly differentiated
tumours (20). Our results confirm this finding.
Namely, amplification of c-myc oncogene was signifi-
cantly associated with advanced tumours of grade 2
compared to grade 1, indicating its role in tumour
progression. However, its correlation with survival of
OSCC patients is not clear (21). 
Contrary to c-myc, EGFR and cycD1 oncogenes
were amplified with relatively low frequency, 16.7%
and 20.0% respectively, in this set of samples. At first
sight, this was an unexpected result because both of
them are frequently amplified in OSCC (5, 11).
However, if we take into consideration mutational
oncogenic activation of H-ras, which appeared at very
high frequency for European population of 33.3%,
the picture becomes more complex but clearer and
even expected. Namely, H-ras is usually induced by
EGFR, which mediates extracellular mitogenic stimuli.
Downstream event of Ras activation may actually be
induction of cycD1 and promotion of cell replication
(22). Ras activates cycD1 promoter via an AP-1 like
sequence (23) and achieves predominant CycD1
nuclear localization. As a consequence, the cells may
acquire ability for non-adherent growth (24) or inde-
pendent cell cycle progression (25). Thus, activation
of either of these oncogenes could have the same
tumorigenic consequence, that is continuous cell
replication, since they act in the same signaling path-
way. Therefore, oncogenic activation of all of them at
the same time could not be justified from biological
point of view and, maybe, we should consider them
as a package. In favor of this is our finding that EGFR
and H-ras were never altered in the same tumour
sample. According to our results, alterations in these
two oncogenes are mutually exclusive. That could be
the explanation for such a low frequency of EGFR
amplification. Lower frequency of cycD1 amplification
(20%) then reported by other authors (11) could be
the consequence of another, additional finding.
Specifically, we have not observed co-alteration of
cycD1 and p16 in any of the analyzed samples. This
is important because cyclin D1 activation and p16
inactivation have the same effect, i.e., an increase in
pRb phosphorylation and progression from G1 to S
phase in the cell cycle (26). Hence, alteration of
either of these genes will have the same outcome and
there is no need for simultaneous changes in both. In
other words, if p16 is inactivated, oncogenic activa-
tion of cycD1 is not necessary and would not be bio-
logically rational. 
One of the tumour suppressor genes most fre-
quently involved in human OSCC is TP53 (27). We
found that it was mutated in 56.7% of tumour sam-
ples, which is within reported frequencies (12).
Inactivation of TP53 was significantly associated with
more advanced primary tumours, grade 2 (p=
0.0004) and pT stage 2 (p=0.0298). Many reports
support this result (12, 28), but there are many which
show that inactivation of TP53 is an early event (29,
30). Opinions about this issue are contradictory.
Moreover, we showed co-alteration of TP53 and c-
myc, i.e., inactivation of TP53 significantly correlated
with the amplification of c-myc in grade 2 tumours.
The interactive involvement of c-myc and TP53 with
cell proliferation and apoptosis, when altered by
mutational events, seems to be a key regulatory ele-
ment of oncogenesis and co-alteration of these two
important genes is considered to be a relatively early
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Figure 2 Methylation specific PCR (MSP) for determination
of methylation status of promoter region of p16 tumour sup-
pressor gene. U – unmethylated; M – methylated; m – length
marker. Arrow indicates a sample with hypermethylated pro-
moter of p16 gene.
aN – number of patients per group; *indicates statistically sig-
nificant values, p≤0.05.
Table VI Association between alterations of c-myc and p53
genes and tumour grade.
Variables
Amplified c-myc oncogene
TP53 mutated
Na (%)
TP53 wt
N (%) p value
G1 1 4
G2 11 1 p = 0.0099*
J Med Biochem 2013; 32 (4) 387
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event in OSCC progression, before significant inva-
sion (reviewed by Papakosta et al (31)).
In conclusion, despite major advances in our
understanding of the molecular pathology of OSCC,
numerous gaps have still to be filled. The most prom-
ising marker remains the TP53 tumour suppressor,
which is the most frequently mutated gene in OSCC.
Since there is synergism between TP53 and c-myc, it
seems that co-alteration of these two genes could be
also a good marker of OSCC progression from
grade1 to grade 2 tumours.
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